HYPR Hyperfine (HYPR) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001833769
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
55
13F, latest reported quarter
What the filings say about HYPR
Insiders, 180 days
-$32.5K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Hyperfine insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Hyperfine, Inc. insiders sold a net $32.5K of stock across 47 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 26, 2026.
- The trade is 1.2% of the 592,420 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and CAO HALE BRETT sold about $6.3K of HYPR on Aug 24, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on May 26, 2026.
- The trade is 1.1% of the 671,256 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer TEISSEYRE THOMAS sold about $6.3K of HYPR on Aug 24, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 23, 2026.
- The trade is 1.0% of the 599,765 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and CAO HALE BRETT sold about $10.0K of HYPR on May 26, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Mar 23, 2026.
- The trade is 0.9% of the 678,601 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer TEISSEYRE THOMAS sold about $10.0K of HYPR on May 26, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Feb 13, 2026.
- The trade is 6.8% of the 354,648 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer TEISSEYRE THOMAS sold about $29.3K of HYPR on Mar 23, 2026, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.47 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$32.5K over 180 days
-$12.5K over 90 days
more than 58% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
55 funds bought in last quarter
below 55% of Medical Devices
Revenue
+5.2% year over year
below 65% of Medical Devices
Margin
-262.3% net margin
below 87% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 8.5 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HYPR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.2%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HYPR: institutional holders (13F)
13F holdings, latest reported quarter
4,673,087 sh
$6.3M
3,380,087 sh
$4.6M
1,960,811 sh
$2.6M
1,742,020 sh
$2.4M
1,320,041 sh
$1.8M
Congress trades in HYPR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HYPR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HYPR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$132.0K position · as of 2026-06-30
0.1%
GuideMark Small/Mid Cap Core Fund
$25.5K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$353.5K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$109.4K position · as of 2026-07-31
0.0%
1290 VT Micro Cap Portfolio
$23.6K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$992.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Not applicable
1 active
What changed recently
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
2026-09-17 · Completion moved 2026-07-31 → 2026-10-31
Not applicable
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
2026-09-17 · Enrolling By Invitation → Active Not Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $32.5K sold by insiders over 180 days, 55 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HYPR financials
Revenue growth
+5.2%
XBRL, annual
Net margin
-262.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$16.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HYPR
| FY Dec 2025 | $13.6M |
| FY Dec 2024 | $12.9M |
| FY Dec 2023 | $11.0M |
| FY Dec 2022 | $6.8M |
| FY Dec 2021 | $1.5M |
| Jun 2026 | $3.9M |
| Mar 2026 | $3.9M |
| Dec 2025 | $5.3M |
| Sep 2025 | $3.4M |
| Jun 2025 | $2.7M |
| Mar 2025 | $2.1M |
| Dec 2024 | $2.3M |
| Sep 2024 | $3.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-210.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HYPR
| FY Dec 2025 | -262.3% |
| FY Dec 2024 | -315.9% |
| FY Dec 2023 | -401.0% |
| FY Dec 2022 | -649.2% |
| FY Dec 2021 | -4,335% |
| Jun 2026 | -238.2% |
| Mar 2026 | -220.9% |
| Dec 2025 | -111.7% |
| Sep 2025 | -320.6% |
| Jun 2025 | -342.2% |
| Mar 2025 | -440.7% |
| Dec 2024 | -447.7% |
| Sep 2024 | -283.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$27.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HYPR
| FY Dec 2025 | -$29.1M |
| FY Dec 2024 | -$39.1M |
| FY Dec 2023 | -$42.6M |
| FY Dec 2022 | -$72.9M |
| FY Dec 2021 | -$49.9M |
| Jun 2026 | -$7.3M |
| Mar 2026 | -$9.2M |
| Dec 2025 | -$5.3M |
| Sep 2025 | -$5.7M |
| Jun 2025 | -$8.4M |
| Mar 2025 | -$9.7M |
| Dec 2024 | -$8.4M |
| Sep 2024 | -$8.7M |
At each fiscal year end
Single quarter
Debt to equity
0.36x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity HYPR
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.36x |
| Mar 2026 | 0.38x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.04x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -2.04x |
| Mar 2026 | -2.11x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-97.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HYPR
| FY Dec 2025 | -79.0% |
| FY Dec 2024 | -61.0% |
| FY Dec 2023 | -42.5% |
| FY Dec 2022 | -28.5% |
| FY Dec 2021 | -103.6% |
| Jun 2026 | -97.0% |
| Mar 2026 | -89.8% |
| Dec 2025 | -79.0% |
| Sep 2025 | -94.0% |
| Jun 2025 | -77.3% |
| Mar 2025 | -67.9% |
| Dec 2024 | -61.0% |
| Sep 2024 | -53.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-64.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HYPR
| FY Dec 2025 | -62.3% |
| FY Dec 2024 | -53.2% |
| FY Dec 2023 | -38.8% |
| FY Dec 2022 | -26.3% |
| FY Dec 2021 | -47.3% |
| Jun 2026 | -64.4% |
| Mar 2026 | -61.2% |
| Dec 2025 | -62.3% |
| Sep 2025 | -72.2% |
| Jun 2025 | -64.6% |
| Mar 2025 | -58.0% |
| Dec 2024 | -53.2% |
| Sep 2024 | -47.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-74.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HYPR
| FY Dec 2025 | -79.2% |
| FY Dec 2024 | -63.8% |
| FY Dec 2023 | -45.7% |
| FY Dec 2022 | -47.4% |
| FY Dec 2021 | -51.0% |
| Jun 2026 | -74.2% |
| Mar 2026 | -72.7% |
| Dec 2025 | -79.2% |
| Sep 2025 | -88.5% |
| Jun 2025 | -80.4% |
| Mar 2025 | -71.2% |
| Dec 2024 | -63.8% |
| Sep 2024 | -57.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HYPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $13.6M | $12.9M | $11.0M | $6.8M |
| Gross profit | $6.8M | $5.9M | $4.8M | $907.0K |
| Operating income | -$37.1M | -$43.2M | -$48.1M | -$73.9M |
| Net income | -$35.6M | -$40.7M | -$44.2M | -$44.2M |
| EPS (diluted) | -0.43 | -0.56 | -0.62 | -1.04 |
| Operating cash flow | -$27.9M | -$38.8M | -$41.8M | -$72.3M |
| Cash | $35.1M | $37.6M | $75.2M | $117.5M |
| Long-term debt | $0 | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
HYPR Stock Sonar score 6/7 axes
Find similar shapesCompareHYPR ranks highest on risk and compliance (65th percentile) and growth (55th), and lowest on profitability (26th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HYPR filings, in plain words
Are Hyperfine insiders buying or selling HYPR?
In the 180 days to 2026-10-28, Hyperfine insiders were net sellers, a net $32.5K across purchases and sales reported on Form 4, by 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Hyperfine insiders were net sellers of HYPR, a net $32.5K across purchases and sales reported on Form 4 by 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
